The promise of cancer immunotherapy lies in the potential to enhance tumor specific CD8+ cytotoxic T cell responses. Pelican Therapeutics are a clinical stage company within the NightHawk Biosciences ecosystem focused on therapeutic targeting of TNFRSF25 (TNF Receptor Superfamily Member 25) to promote the expansion of effector T cells and maximize the potential of the immune system to mount effective anti-tumor responses.
Our Technology Our Pipeline Latest News
